[Federal Register: March 10, 2004 (Volume 69, Number 47)]
[Page 11446]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]

[[Page 11446]]



Food and Drug Administration

Allergenic Products Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.


    This notice announces a forthcoming meeting of a public advisory 
committee of the Food and Drug Administration (FDA). The meeting will 
be open to the public.
    Name of Committee: Allergenic Products Advisory Committee.
    General Function of the Committee: To provide advice and 
recommendations to the agency on FDA's regulatory issues.
    Date and Time: The meeting will be held via teleconference on April 
2, 2004, from 1 p.m. to 3:40 p.m.
    Location: Food and Drug Administration, Bldg. 29B, Conference Rooms 
A & B, 8800 Rockville Pike, Bethesda, MD. This meeting will be held by 
teleconference. The public is welcome to attend the meeting at the 
above location. A speaker phone will be provided at the specified 
location for public participation in this meeting.
    Contact Person: William Freas or Jane Brown, Center for Biologics 
Evaluation and Research (HFM-71), Food and Drug Administration, 1401 
Rockville Pike, Rockville, MD 20852, 301-827-0314, or FDA Advisory 
Committee Information Line, 1-800-741-8138 (301-443-0572 in the 
Washington, DC area), code 3014512388. Please call the Information Line 
for up-to-date information on this meeting.
    Agenda: On April 2, 2004, the committee will hear updates on the 
following topics: Personnel organization, research and regulatory work 
of the Laboratory of Immunobiochemistry in the Division of Bacterial, 
Parasitic and Allergenic Products, Center for Biologics and an update 
on FDA activities relating to cockroach standardization. The committee 
will then discuss use of microarray technology in allergen 
    Procedure: On April 2, 2004, from 1 p.m. to 3:40 p.m., the meeting 
is open to the public. Interested persons may present data, 
information, or views orally or in writing on issues pending before the 
committee. Written submissions may be made to the contact person by 
March 25, 2004. Oral presentations from the public will be scheduled 
between approximately 2:40 p.m. and 3:40 p.m. Time allotted for each 
presentation may be limited. Those desiring to make formal oral 
presentations should notify the contact person before March 29, 2004, 
and submit a brief statement of the general nature of the evidence or 
arguments they wish to present, the names and addresses of proposed 
participants, and an indication of the approximate time requested to 
make their presentation.
    Persons attending FDA's advisory committee meetings are advised 
that the agency is not responsible for providing access to electrical 
    FDA welcomes the attendance of the public at its advisory committee 
meetings and will make every effort to accommodate persons with 
physical disabilities or special needs. If you require special 
accommodations due to a disability, please contact William Freas or 
Jane Brown at least 7 days in advance of the meeting.
    Notice of this meeting is given under the Federal Advisory 
Committee Act (5 U.S.C. app. 2).

    Dated: March 4, 2004.
William K. Hubbard,
Associate Commissioner for Policy and Planning.
[FR Doc. 04-5405 Filed 3-9-04; 8:45 am]